Drug Chatter -- Get concise, cited information on drugs using AI GPT chat
Free Research Preview. DrugChatter may produce inaccurate information.

How does repatha differ from statins?

See the DrugPatentWatch profile for repatha

How Repatha Works Compared to Statins

Repatha (evolocumab) is a PCSK9 inhibitor that targets a protein called PCSK9, which normally breaks down LDL receptors in the liver. By blocking PCSK9, Repatha increases LDL receptor activity, pulling more LDL cholesterol from the blood for clearance.[1] Statins, like atorvastatin (Lipitor) or rosuvastatin (Crestor), block HMG-CoA reductase, an enzyme in the cholesterol production pathway, reducing the liver's output of LDL cholesterol.[2]

When Doctors Choose Repatha Over Statins

Repatha treats high cholesterol in patients who can't reach LDL goals on statins alone, have statin intolerance (like muscle pain), or have familial hypercholesterolemia. Statins are first-line for most people with high cholesterol or heart disease risk, as guidelines recommend starting there.[3] Repatha adds 50-70% more LDL reduction on top of statins, versus statins' 20-60% alone.[1][2]

Administration and Dosing Differences

Statins are daily oral pills, simple for long-term use. Repatha is a self-injected shot every two weeks or monthly via autoinjector, which some patients find less convenient but others prefer for fewer doses.[1]

Side Effects Patients Report

Statins commonly cause muscle aches (5-10% of users), liver enzyme rises, or rare rhabdomyolysis. Repatha leads to injection-site reactions (5%), flu-like symptoms, or back pain, with fewer muscle issues—making it suitable for statin non-responders.[1][2] No head-to-head trials show one safer overall, but Repatha avoids statin-related diabetes risk increases.

Cost and Access Breakdown

Statins are cheap generics ($10-50/month), widely covered by insurance. Repatha costs $5,000-6,000/year before discounts, often requiring prior authorization for "statin failure." Patient assistance programs exist, but out-of-pocket can hit $500+/month without coverage.[4]

Who Makes Them and Patent Status

Amgen makes Repatha, approved in 2015; its main patents expire around 2030-2034, with biosimilar challenges possible sooner.[5] Statins are mostly off-patent from Pfizer (Lipitor), AstraZeneca (Crestor), and generics.

[1] Repatha prescribing information, Amgen.
[2] Statin guidelines, American College of Cardiology.
[3] FDA label for evolocumab.
[4] GoodRx pricing data.
[5] DrugPatentWatch.com



Other Questions About Repatha :

Is repatha more effective than praluent? Is repatha an injection or a pill?




DrugPatentWatch - Make Better Decisions
© thinkBiotech LLC 2004 - 2026. All rights reserved. Privacy